Visterra Inc.
Kevin Spielberger is an accomplished scientist specializing in antibody development and aptamer design. Currently serving as an Antibody Alchemist at Visterra Inc. since February 2020, Kevin focuses on transforming antibodies into therapeutic medicines. Previously, as an Affinity Selection Engineer at GlaxoSmithKline from July 2011 to February 2020, Kevin designed innovative DNA and RNA aptamers through the SELEX methodology, contributed to generating high-affinity aptamers, and led a radiation safety program. Kevin also held a fellowship with the International AIDS Vaccine Initiative (IAVI) as part of the Kenya AIDS Vaccine Initiative, where responsibilities included protocol development and optimizing experimental procedures in Nairobi. Earlier roles include Senior Research Associate at Archemix and Research Associate at US Genomics, further cementing expertise in aptamer research and development. Kevin is an alumnus of Northeastern University.
This person is not in the org chart
Visterra Inc.
1 followers
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. andchanged its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.